Three drugs are unnecessary for treating paucibacillary leprosy—A critique of the WHO guidelines

This publication has 10 references indexed in Scilit:

• Single-dose rifampicin chemoprophylaxis protects those who need it least and is not a cost-effective intervention
  PLOS Neglected Tropical Diseases, 2018
• Uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): Results of an open label, randomized and controlled clinical trial, among multibacillary patients
  PLOS Neglected Tropical Diseases, 2017
• Leprosy reactions: The predictive value of Mycobacterium leprae-specific serology evaluated in a Brazilian cohort of leprosy patients (U-MDT/CT-BR)
  PLOS Neglected Tropical Diseases, 2017
• Outcome of 6 months MBMDT in MB patients in Bangladesh- preliminary results
  Leprosy Review, 2016
• WHO Multidrug Therapy for Leprosy: Epidemiology of Default in Treatment in Agra District, Uttar Pradesh, India
  BioMed Research International, 2015
• Brazilian clinical trial of uniform multidrug therapy for leprosy patients: the correlation between clinical disease types and adverse effects
  Memórias do Instituto Oswaldo Cruz, 2012
• Hypersensitivity Reactions to Dapsone: A Systematic Review
  Acta Dermato-Venereologica, 2012
• Comparative study of Uniform-MDT and WHO MDT in Pauci and Multi bacillary leprosy patients over 24 months of observation
  Leprosy Review, 2009
• The INFIR Cohort Study: investigating prediction, detection and pathogenesis of neuropathy and reactions in leprosy. Methods and baseline results of a cohort of multibacillary leprosy patients in North India
  Leprosy Review, 2005
• MDT-MB therapy in paucibacillary leprosy: A clinicopathological assessment
  Indian Journal of Dermatology, Venereology and Leprology, 2005